Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC.

Further, results for ORR, PFS after first subsequent therapy, and OS in the Japanese subpopulation were largely consistent with those of the overall population and showed a favorable trend for amivantamab–chemotherapy versus chemotherapy.

also in 993 other papers